9月份中国物流业景气指数为51.2%，较上月上升0.3个百分点。从分项指数看，物流业务总需求保持扩 张，新订单指数在扩张区间内加速扩张。铁路运输业、道路运输业、航空运输业、多式联运领域和邮政 快递业新订单指数，环比回升均超过0.5个百分点。 资讯编辑：沈一冰 021-26093395 中国物流与采购联合会11日公布9月份中国物流业景气指数。9月份供应链上下游产供销有效衔接，物流 需求增长平稳，物流业景气水平继续提升。 资讯监督：乐卫扬 021-26093827 资讯投诉：陈跃进 021-26093100 免责声明：Mysteel发布的原创及转载内容，仅供客户参考，不作为决策建议。原创内容版权归Mysteel 所有，转载需取得Mysteel书面授权，且Mysteel保留对任何侵权行为和有悖原创内容原意的引用行为进 行追究的权利。转载内容来源于网络，目的在于传递更多信息，方便学习与交流，并不代表Mysteel赞 同其观点及对其真实性、完整性负责。 ...

Core Viewpoint - Joby Aviation has experienced a stock price pullback of over 20% after a significant rally, but this decline is seen as a healthy consolidation rather than a sign of weakness, especially following the completion of its acquisition of Blade Air Mobility's passenger business [1][2][10]. Group 1: Stock Performance and Market Sentiment - Joby Aviation's stock surged from under $9 in early June to above $20 in August, followed by a pullback attributed to automated insider selling and profit-taking by retail investors [1]. - The recent decline in stock price is interpreted as long-term investors taking profits rather than a new wave of bearish sentiment, as evidenced by a nearly 13% decrease in short interest [4][5]. Group 2: Acquisition of Blade Air Mobility - The acquisition of Blade Air Mobility's passenger business, completed on August 29, significantly strengthens Joby's business fundamentals, providing immediate scale and operational capabilities [7][9]. - Blade's passenger segment generated approximately $25.7 million in revenue with a positive Passenger Adjusted EBITDA of around $2.4 million and a 30.5% Flight Margin, indicating strong profitability compared to the airline sector's average of 3% to 4% [8]. Group 3: Strategic Advantages and Future Opportunities - The acquisition addresses key commercialization challenges ahead of schedule, providing a de-risked commercial plan and access to Blade's loyal customer base of over 50,000 annual passengers [9][13]. - Joby Aviation is set to demonstrate its capabilities in Japan with partner ANA Holdings at EXPO 2025, starting October 1, which is expected to shift market attention back to the company's growth potential [11][12].

Company Overview - Blade Air Mobility, Inc. is changing its legal name to Strata Critical Medical, Inc. to focus on mission-critical logistics and medical services for hospitals and healthcare providers [1][2] - The company is one of the largest transporters of human organs for transplant in the United States and provides air transportation and logistics services primarily in the Northeast United States, Southern Europe, and Western Canada [3] Stock Information - The name change will take effect on August 28, 2025, and the company's common stock will begin trading under the symbol "SRTA" on August 29, 2025 [2] - The CUSIP numbers for the company's common stock and warrants will remain unchanged, and no action is required from securityholders [2] Business Model - Blade operates an asset-light model with exclusive passenger terminal infrastructure and proprietary technologies, facilitating a transition to Electric Vertical Aircraft (EVA or eVTOL) for lower-cost, quiet, and emission-free air mobility [3]

Core Insights - Blade Air Mobility reported Q2 2025 GAAP revenue of $70.8 million, exceeding analyst expectations by 10.5% [1][2] - The company plans to divest its Passenger division to Joby Aviation, transitioning to a specialized medical air mobility operator [1][8] - The medical segment showed significant year-over-year growth, while free cash flow turned negative due to increased maintenance costs [1][6] Financial Performance - Q2 2025 GAAP revenue was $70.8 million, up 4.3% from $67.9 million in Q2 2024 [2] - Adjusted EBITDA increased to $3.2 million, a 220% rise from $1.0 million in the previous year [2] - Free cash flow was negative at $(5.7) million, a decline of 191.9% from a positive $6.2 million in Q2 2024 [2] Business Focus and Strategy - Blade operates two main lines: on-demand passenger flights and MediMobility Organ Transport services [3] - The divestiture of the Passenger segment will allow Blade to focus on critical healthcare logistics and rebrand as Strata [3][8] - The company aims to optimize operations and prepare for the adoption of Electric Vertical Aircraft (eVTOL) technology [4][12] Segment Performance - The medical segment generated $45.1 million in revenue, a 17.6% increase year-over-year [5] - Medical Flight Margin (non-GAAP) decreased to 22.0% from 23.6% due to higher maintenance costs [6] - The Passenger segment's revenue fell 13.2% to $25.7 million, with a flight margin improvement to 30.5% [7] Future Outlook - Management expects the transition to a dedicated medical air mobility company to be neutral to Adjusted EBITDA and Free Cash Flow [9] - Full-year 2025 revenue is projected between $245 million and $265 million, with adjusted EBITDA in the double-digit millions [14] - Key factors for future success include execution of medical growth initiatives and integration of eVTOL aircraft [15]

Financial Data and Key Metrics Changes - The company announced a sale of the Blade passenger business to Joby Aviation for up to $125 million, which is expected to create long-term value for stakeholders [6][9] - Medical revenue grew 17.6% year-over-year to a record $45.1 million in Q2 2025, driven by new transplant center customers and increased demand [18][26] - Adjusted EBITDA margin for the medical segment rose to 13.4% in Q2 2025, compared to 11.4% in Q1 2025, but declined from 14.4% in Q2 2024 [18][20] Business Line Data and Key Metrics Changes - The medical business accounted for approximately 60% of revenue in 2024, up from 12% in 2020, and contributed about 85% of the segment's adjusted EBITDA [6][9] - The passenger business saw a 5.5% decrease in short-distance revenue year-over-year, primarily due to lower revenue in the US segment [20] - The passenger segment adjusted EBITDA tripled year-over-year from $800,000 to $2.4 million, driven by improved flight margins and lower SG&A expenses [22] Market Data and Key Metrics Changes - The company exited the Canadian market in August 2024, impacting short-distance revenue in the US [20] - European operations showed strong revenue growth due to realignment with local partners and operational changes [21] Company Strategy and Development Direction - The company aims to focus on its medical division as a standalone entity, which will be renamed Strata Critical Medical, emphasizing its growth potential in the medical sector [6][9] - A disciplined capital allocation strategy is planned, supported by approximately $200 million in cash from the passenger business sale [12][26] - The company is entering a long-term partnership with Joby Aviation to access eVTOL aircraft for medical use, enhancing its service offerings [15][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects of the medical business, expecting mid-teens revenue growth in the second half of 2025 [26] - The company anticipates improved fleet uptime and adjusted EBITDA margins in the medical segment, projecting margins of approximately 15% [26] - Management noted that the divestiture is expected to be neutral to adjusted EBITDA and free cash flow on a go-forward basis [25][26] Other Important Information - The company ended the quarter with no debt and $113.4 million in cash and short-term investments [25] - The financial impact of the divestiture is expected to be adjusted EBITDA and free cash flow neutral, supported by estimated corporate cost efficiencies of $7 million [10][25] Q&A Session Summary Question: What are the current priorities for capital allocation post-transaction? - Management highlighted opportunities in M&A and organic growth, emphasizing the need for capital to scale the business effectively [29][30] Question: Are there any operational impacts from the divestiture on the medical segment? - Management stated that the company is set up for success as a standalone entity and expects the partnership with Joby to add significant value [32][33] Question: Why was the passenger business sold now? - Management indicated that the market was discounting the value of the passenger business, and the divestiture allows for a clearer focus on the high-growth medical segment [37][38] Question: What is the growth outlook for the medical business? - Management expressed optimism about organic growth driven by new technologies and services, aiming for high teens adjusted EBITDA margins in the long term [41][43] Question: How is the business trending quarter to date? - Management reported strong performance in July, with no signs of seasonal slowdown yet [44] Question: What are the tax implications of the transaction? - Management noted that they have enough NOLs to offset capital gains from the divestiture, expecting minimal cash tax impact [46]

Transaction Overview - Blade Passenger division 将以高达 1.25 亿美元的价格出售给 Joby Aviation[9]，这笔交易的价格可能会以现金或 Joby 股票支付[10] - Blade 的医疗部门将保留公开上市资格，并更名为 Strata Critical Medical ("Strata")，成为一家纯粹的合同医疗业务公司[9] - 预计资产剥离在调整后的 EBITDA 和自由现金流方面将保持中性，并得到约 700 万美元的年度企业成本效率的支持[9] Financial Performance (Q2 2025) - Medical 部门收入同比增长 18%[18] - Passenger 部门收入同比下降 13%[13] - Medical 部门调整后的 EBITDA 利润率为 13.4%，同比下降 1 个百分点[18] - Passenger 部门调整后的 EBITDA 同比增长 160 万美元[18] - 短途收入（不包括加拿大）同比下降 6%[18] Medical Segment Growth Drivers - 2018 年至 2024 年，心脏、肝脏和肺移植距离增加了 64%[38] - Blade 在器官移植航空物流领域的市场份额估计约为 30%[40] - 地面运输的总潜在市场为 2 亿美元[46] - 器官配置服务的总潜在市场约为 2.5 亿美元[53] Trinity Air Medical Acquisition Impact - 截至 2024 年 9 月 30 日的 12 个月内，Blade/Trinity Medical 部门的总收入约为 1.42 亿美元，分部调整后的 EBITDA 为 1630 万美元[62]

Core Insights - Blade Air Mobility, Inc. reported a 4.2% increase in revenue to $70.8 million for Q2 2025 compared to $67.9 million in Q2 2024, driven primarily by growth in the Medical segment [9][12] - The company announced the sale of its Passenger division to Joby Aviation for up to $125 million, while the Medical division will remain a standalone public company, rebranding as Strata Critical Medical [6][8] - Net loss improved significantly by $7.6 million year-over-year to $(3.7) million in Q2 2025, with Adjusted EBITDA increasing by $2.2 million to $3.2 million [6][14] Financial Results - Total revenue for the six months ended June 30, 2025, was $125.1 million, up 4.7% from $119.5 million in the same period of 2024 [3][9] - Cost of revenue increased by 2.9% to $53.1 million in Q2 2025, while total operating expenses decreased by 5.4% to $75.8 million [3][9] - Gross profit rose to $12.9 million in Q2 2025, reflecting a gross margin improvement to 18.2% from 16.7% in Q2 2024 [3][9] Segment Performance - Medical revenue increased by 17.6% year-over-year to $45.1 million in Q2 2025, while Passenger segment revenue decreased by 13.2% to $25.7 million [9][35] - Flight profit for the Medical segment was $9.9 million, with a flight margin of 22.0%, while the Passenger segment achieved a flight profit of $7.8 million and a flight margin of 30.5% [39][40] - The company reported a decrease in Short Distance revenue by 17.8% to $17.2 million, attributed to reduced demand following a helicopter incident and inclement weather [9][14] Strategic Updates - The divestiture of the Passenger division is expected to be neutral to Adjusted EBITDA and Free Cash Flow on a go-forward basis, supported by estimated corporate cost efficiencies of approximately $7 million [9][12] - Blade's Medical division will focus on contractual healthcare solutions with no direct reimbursement risk, aiming for a strong growth profile [8][9] - The company ended Q2 2025 with $113.4 million in cash and short-term investments, positioning itself for future growth and strategic investments [14][12]

A major move that could shape the future of flying. Joby Aviation, maker of an electric helicopter airplane hybrid, agreeing to acquire Blade Air Mobility, essentially an Uber for helicopters. Joby plans to shell out $125 million in the deal, hoping to turbocharge its goal, building a fleet of electric flying taxis, like something out of a sci-fi movie.Joby telling CNBC this morning, the acquisition gives it an existing customer base and more takeoff and landing spots. What we're excited about is taking our ...

Core Viewpoint - Blade Air Mobility, Inc. has announced the sale of its passenger division to Joby Aviation for up to $125 million, allowing Blade to focus on its medical logistics business, which will rebrand as Strata Critical Medical [1][9][10]. Company Overview - Blade Air Mobility provides air transportation and logistics, primarily for hospitals in the U.S., and is one of the largest transporters of human organs for transplant [12]. - Joby Aviation is developing an all-electric vertical take-off and landing air taxi service, intending to operate and sell its aircraft globally [14]. Transaction Details - The sale price for the passenger division is up to $125 million, which may be paid in cash or Joby stock, including up to $35 million in performance-based earnouts [10]. - The transaction is expected to close in the coming weeks, with a new ticker for Strata to be announced later [11]. Strategic Focus Post-Transaction - Following the divestiture, Strata will concentrate on its medical logistics and services, leveraging its asset-light platform to enhance its offerings and pursue growth through acquisitions [2][8]. - The medical division represented approximately 84% of Blade's Segment Adjusted EBITDA and 59% of its revenue in 2024, indicating a strong focus on this profitable segment [8]. Leadership Changes - Rob Wiesenthal, the current CEO of Blade, will join Joby as CEO of Blade Air Mobility and serve as Chairman of Strata [5]. - Will Heyburn and Melissa Tomkiel will become Co-CEOs of Strata while retaining their existing roles [6]. Partnership and Future Opportunities - A long-term partnership between Joby and Strata will provide access to Joby aircraft for medical use, enhancing Strata's service capabilities [4][9]. - The expected operational efficiencies from the divestiture are estimated at approximately $7 million annually, making the financial impact neutral in terms of Adjusted EBITDA and Free Cash Flow [5][9].

Company Overview - Blade Air Mobility, Inc. is a provider of air transportation and logistics services, primarily for hospitals and passengers in the United States and Southern Europe [3] - The company is one of the largest transporters of human organs for transplant and offers helicopter and fixed-wing services [3] - Blade operates an asset-light model with exclusive passenger terminal infrastructure and proprietary technologies, facilitating a transition to Electric Vertical Aircraft (EVA or eVTOL) for lower-cost, quiet, and emission-free air mobility [3] Upcoming Financial Results - Blade will release its financial results for the second quarter ended June 30, 2025, on August 5, 2025, before the market opens [1] - A conference call will be held on the same day at 8:00 am Eastern Time, hosted by the CEO and CFO, including a question-and-answer session [1][2]